Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs RCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: MXCT 0 – 5 RCEL (1 Tie) Matrix Metrics: MXCT 1 – 9 RCEL

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs RCEL
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.54β · 65% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.1% over 20 days), RSI 52
RSI-14: 51.5 · SMA20: $16.14 · SMA50: $13.96

6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 5 RCEL)

Columns: Metric · MXCT · RCEL
1. Valuation Multiples RCEL
Forward P/E N/M 10.3x
Trailing P/E N/M 10.3x
PEG Ratio N/M N/M
EV / Revenue 3.9x 6.4x
2. Growth & Scale RCEL
Revenue Growth (YoY) +48.7% +53.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $34M $85M
Market Cap $132.2M $506.7M
3. Profitability & Quality RCEL
Gross Margin 81.0% 82.4%
Operating Margin -85.5% -33.9%
Net Profit Margin -81.4% -42.6%
Return on Equity (ROE) -16.9% -1746.3%
4. Balance Sheet & Cash Flow RCEL
Cash Generation (TTM) -$24M -$20M
Cash Flow Margin -69.2% -23.6%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $37M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 84.7% (6th %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (1) vs RCEL (9)
Institutional Metric MXCT RCEL Criterion Row Edge
Market Capitalization
Scale
$132.2M $506.7M Larger Scale RCEL
Trailing P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Forward P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+48.7% +53.1% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-85.5% -33.9% Higher Margin RCEL
Net Profit Margin
Profitability
-81.4% -42.6% Higher Margin RCEL
Return on Equity (ROE)
Capital Efficiency
-16.9% -1746.3% Higher ROE MXCT
52-Week Range Position
Momentum
63% ($1–$2) 82% ($3–$18) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 1.54β · 65% Vol Lower Realized Risk RCEL
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 45.6 / 100 (HOLD) Higher Composite RCEL
Trailing 12M Revenue (USD)
Operating Scale
$34M $85M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 82.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 6.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) -$20M ($37M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +5.5 pp
MXCT: -4.2% · RCEL: +1.3%
3M Horizon RCEL +59.06 pp
MXCT: -1.44% · RCEL: +57.62%
6M Horizon RCEL +209.32 pp
MXCT: +31.73% · RCEL: +241.05%
1Y Horizon RCEL +314.85 pp
MXCT: -19.41% · RCEL: +295.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue RCEL Revenue MXCT Op. Margin RCEL Op. Margin Margin Leader
FY2018 N/A $0M N/A -1489.9% RCEL
FY2019 $10M $10M -93.7% -466.4% MXCT
FY2020 $20M $10M -71.6% -299.2% MXCT
FY2021 $20M $30M -84.3% -90.8% MXCT
FY2022 $30M $30M -95.2% -79.9% RCEL
FY2023 $20M $50M -247.7% -85.1% RCEL
FY2024 $20M $60M -230.5% -88.1% RCEL
FY2025 $20M $70M -247.6% -59.4% RCEL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCEL CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 84.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $506.7M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs RCEL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin). Technically, MXCT sits in a Markup phase (RSI 55.3, UNCLASSIFIED options structure) and RCEL sits in a Markup phase (RSI 51.5, CONSOLIDATION options structure).

RCEL leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with RCEL at +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MXCT cumulative revenue shifted +100.0% while RCEL shifted +600.0%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCEL.

RCEL screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus RCEL (-1746.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.